• 3-Deazaadenosine: Mechanism, Evidence & Use

  2026-09-24

  3-Deazaadenosine is a S-adenosylhomocysteine hydrolase inhibitor that can alter cellular methylation by increasing intracellular SAH and changing the SAH-to-SAM ratio. Product information also reports preclinical antiviral activity against Ebola and Marburg viruses, but these findings do not establish clinical efficacy or direct effects on m6A pathways.

• 3-Deazaadenosine: Global vs Targeted Methylation

  2026-09-23

  3-Deazaadenosine is an S-adenosylhomocysteine hydrolase inhibitor that can perturb methylation broadly, but it is not a selective probe of METTL14 or RNA m6A. This article uses a recent ulcerative colitis study to show how to distinguish metabolic methylation effects from transcript-specific regulation when designing and interpreting experiments.

• Dovitinib (TKI-258): RTK Signaling Research

  2026-09-23

  Dovitinib, also called TKI-258 and CHIR-258, is a multitargeted receptor tyrosine kinase inhibitor used to study FLT3, c-Kit, FGFR, VEGFR, and PDGFR signaling. Its reported low-nanomolar activity and downstream effects make it a useful research tool for apoptosis induction in cancer cells, but assay conditions and model context must guide interpretation.

• ATRX Deficiency Sensitizes Glioma to RTK Inhibitors

  2026-09-22

  The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data with temozolomide support ATRX-aware pharmacology and clinical-trial stratification, while remaining preliminary because the evidence is primarily cellular.

• tRF16–ALKBH5–NFKBIA Axis in Osteoarthritis

  2026-09-22

  This study identifies tRF16 as an overexpressed small RNA that worsens osteoarthritis through an ALKBH5–NFKBIA–NF-κB regulatory axis. By combining patient cartilage, an OA rat model, and IL-1β-treated chondrocytes, the work connects tRF-mediated epitranscriptomic regulation with inflammatory cartilage damage and proposes a mechanistically testable biomarker pathway.

• Romidepsin (FK228): Mechanism-to-Assay Research Guide

  2026-09-21

  Explore how Romidepsin (FK228) links selective HDAC1/2 inhibition with chromatin, apoptosis, and cell-cycle phenotypes. This guide also translates multidimensional proteomics into a practical framework for validating target engagement rather than relying on viability data alone.

• TOP1, cGAS, and PD-L1 in Cervical Cancer

  2026-09-21

  The reference study identifies a mechanistic link between HPV oncoproteins, TOP1-associated DNA damage responses, cGAS activation, and PD-L1 expression in cervical cancer. Its findings position the TOP1–cGAS–PD-L1 axis as a useful framework for studying how viral oncogenesis connects genomic stress with tumor-promoting inflammation and immune evasion.

• Dual-Pathway Nanotherapy for Gefitinib Resistance

  2026-09-20

  Deng and colleagues developed a rational combination strategy that pairs gefitinib with crizotinib to suppress PI3K–AKT signaling and compensatory ERK activation in gefitinib-resistant lung adenocarcinoma. Integrated transcriptomics, phospho-proteomics, cell models, xenografts, zebrafish metastasis assays, and a dual-drug nanoparticle platform provide a multiscale framework for addressing both resistance and metastatic progression.

• Cepharanthine in Endometriosis: Organoid and In Vivo Evidenc

  2026-09-19

  A 2026 study evaluated Cepharanthine across immortalized stromal cells, patient-derived endometriotic cells, eutopic endometrial organoids, and a murine peritoneal model. Its central finding is that this biscoclaurine alkaloid suppresses lesion growth through cell-cycle arrest, DNA damage with impaired repair, and mitochondria-associated apoptosis, while also demonstrating the value of organoids for preclinical endometriosis research.

• iRhom2 in Olfaction: OR Regulation and Adaptation

  2026-09-18

  Azzopardi and colleagues identify iRhom2 as an olfactory sensory neuron regulator linked to odorant receptor expression and activity-dependent adaptation. Their combination of knockout-mouse transcriptomics, spatial validation, and heterologous receptor activation supports an iRhom2–ADAM17 signaling model while leaving several causal and translational questions open.

• Indometacin Sodium: Assay Workflows & Optimization

  2026-09-18

  Build reproducible inflammation, proliferation, oligodendrocyte differentiation, and pathway assays with Indometacin Sodium Trihydrate. This practical guide connects concentration selection, vehicle control, mechanistic readouts, and troubleshooting to help researchers distinguish COX-dependent effects from broader cellular responses.

• Danazol Assay Workflows for Endocrine Research

  2026-09-17

  This scenario-based guide explains how Danazol supports reproducible cell viability, steroidogenesis, and endocrine-model workflows. It connects mechanistic benchmarks with practical solvent, storage, control, and vendor-selection decisions for research use of SKU C3644.

• Angiotensin Peptides Enhance SARS-CoV-2 Binding

  2026-09-17

  Oliveira et al. show that naturally occurring angiotensin peptides can increase SARS-CoV-2 spike-protein binding to host receptors, with N-terminally truncated forms producing particularly strong effects. The study provides a mechanistic link between renin–angiotensin biology and viral receptor engagement while also defining important experimental limits: the evidence comes from binding assays rather than infection or clinical studies.

• X-Gal for Reproducible Reporter Workflows

  2026-09-16

  This scenario-based guide explains how X-Gal (SKU A2539) supports β-galactosidase reporter assays, blue-white colony screening, and molecular cloning while avoiding common interpretation errors in viability and cytotoxicity experiments. It covers substrate compatibility, stock handling, data interpretation, and practical vendor-selection criteria.

• Ang II–HIF-1α–HILPDA Axis in NPC Radioresistance

  2026-09-16

  This study identifies a local angiotensin II–AGT–HIF-1α–HILPDA circuit that suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma. Its combination of mechanistic cell biology, radiosensitivity assays, xenograft validation, and tissue analysis supports angiotensin II blockade plus ferroptosis induction as a strategy for further investigation.

8038 records 4/536 page Previous Next 12345 下5页 Last page